venglustat GZ/SAR402671

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Healthy VolunteersParkinson's DiseasePolycystic Kidney, Autosomal Dominant

Phase 1

Effect of Venglustat in Patients With Renal Impairment

CompletedNCT03687554

Genzyme, a Sanofi CompanyHealthy Volunteers, Polycystic Kidney, Autosomal Dominant

Start: 2018-10-05End: 2019-02-27Updated: 2022-04-25

Phase 2

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

TerminatedNCT02906020

Genzyme, a Sanofi CompanyParkinson's Disease

Start: 2016-12-15End: 2021-05-27Updated: 2022-05-24

Related Papers

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

2023-08-0151 citations

Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers.

2023-06-031 citations

Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein

Movement Disorders2023-04-1213 citations

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Journal of Parkinson s Disease2021-12-1059 citations